AP26113
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Background Lung cancer is the most common cancer worldwide as well as the leading cause of cancer-related deaths. Non-small cell…
Chromosomal rearrangement mediated gene fusions and activation of oncogenic signaling pathways have become druggable targets for…
AbstractThe therapeutic targeting of anaplastic lymphoma kinase (ALK) has been a burgeoning area of research since 2007 when ALK…
Phosphorus, despite its abundance in the human body, is rarely found in drug molecules, with clinical utility limited to a few…
Rearranged or mutated forms of the Anaplastic Lymphoma Kinase (ALK) are involved in the pathogenesis of various cancers, in…
All patients with oncogenic driver mutations in non-small cell lung cancer (NSCLC) who are treated with a targeted agent will…
ABSTRACT Aim: AP26113 is an investigational orally-active tyrosine kinase inhibitor with preclinical activity against ALK and all…
ALK is a tyrosine kinase receptor involved in a broad range of solid and haematological tumors. It has been shown that about 70…
Activating gene rearrangements of anaplastic lymphoma kinase (ALK) have been identified in anaplastic large cell lymphoma (ALCL…